The Safety and Benefit of Statins in Liver Cirrhosis: A Review

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 10, 2015, Pages 577-580

  Souk, K ^a   Al Badri, M ^a   Azar, S T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

decompensation; hepatocellular carcinoma; liver cirrhosis; safety; statins

Indexed keywords

ALANINE AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RISK; DECOMPENSATED LIVER CIRRHOSIS; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER PERFUSION; LIVER PROTECTION; LIVER TOXICITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PORTAL HYPERTENSION; PRIORITY JOURNAL; RISK REDUCTION; SEPSIS; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VARICEAL HEMORRHAGE; ANIMAL; CORONARY ARTERY DISEASE; METABOLISM;

ANIMALS; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER CIRRHOSIS;

EID: 84948423240     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0035-1564093     Document Type: Article

References (38)

1. Roger V. L., Go A. S., Lloyd-Jones D. M. et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation: 2011; 123 e18 e209
2. Nicholls S., Lundman P. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Semin Vasc Med: 2004; 4 187 195
3. Cohen J. D., Cziraky M. J., Cai Q. et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol: 2010; 106 969 975
4. cdc info@cdc.gov. Centers for disease control and prevention. National Center for Health Statistics [Accessed 2012]
5. Blachier M., Leleu H., Peck-Radosavljevic M. et al. The burden of liver disease in Europe: a review of available epidemiological data. The European Association for the Study of the Liver: 2013; 978-2-8399-1176-4
6. Targher G., Bertolini L., Padovani R. et al. Differences and similarities in early atherosclerosis between patients with nonalcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol: 2007; 46 1126 1132
7. Kalaitzakis E., Rosengren A., Skommevik T. et al. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci: 2010; 55 467 475
8. Parra J. L., Reddy K. R. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis: 2003; 7 415 433
9. Calderon R. M., Cubeddu L. X., Goldberg R. B. et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc: 2010; 85 349 356
10. Argo C. K., Loria P., Caldwell S. H. et al. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology: 2008; 48 662 669
11. Forrester J. S., Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol: 2007; 99 732 738
12. Chang C. Y., Schiano T. D. Drug hepatotoxicity. Aliment Pharmacol Ther: 2007; 25 1135 1151
13. Bhardwaj S. S., Chalasani N. Lipid lowering agents that cause drug induced hepatotoxicity. Clin Liver Dis: 2007; 11 597 613
14. Tolman K. G. The liver and lovastatin. Am J Cardiol: 2002; 89 1374 1380
15. Russo M. W., Jacobson I. M. How to use statins in patients with chronic liver disease. Cleve Clin J Med: 2004; 71 58 62
16. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology: 2005; 41 690 695
17. Khorashadi S., Hasson N. K., Cheung R. C. et al. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol: 2006; 4 902 907
18. William N., Mahmud M. Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review. Curr Atheroscler Rep: 2013; 15 305
19. Avins A. L., Manos M. M., Zhao W. et al. Hepatic effects of lovastatin exposure in patients with liver disease. Drug Saf: 2008; 31 325 334
20. Sonal K., Norman D., Grace Amir A. et al. Statin use in patients with cirrhosis: A retrospective cohort study. Dig Dis Sci: 2014; 10.1007/s10620-014-3179-2
21. Bhathal P. S., Grossman H. J. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol: 1985; 1 325 329
22. Gupta T. K., Toruner M., Chung M. K. et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology: 1998; 28 926 931
23. Dangas G., Smith D. A., Unger A. H. et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost: 2000; 83 688 692
24. Kalinowski L., Dobrucki L. W., Brovkovych V. et al. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation: 2002; 105 933 938
25. Kureishi Y., Luo Z., Shiojima I. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med: 2000; 6 1004 1010
26. Carmen Z., Juan G. Abraldes et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology: 2004; 126 749 755
27. Juan G. Abralde Albillos A. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology: 2009; 136 1651 1658
28. Kim W. R., Brown R. S. Jr, Terrault N. A. et al. Burden of liver disease in the United States: summary of a workshop. Hepatology: 2002; 36 227 242
29. Cazzaniga M., Dionigi E., Gobbo G. et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in hospital outcome. J Hepatol: 2009; 51 475 482
30. Istvan E. S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science: 2001; 292 1160 1164
31. Motzkus-Feagans C., Pakyz A. L., Ratliff S. M. et al. Statin use and infections in veterans with cirrhosis. Aliment Pharmacol Ther: 2013; 38 611 618
32. Jemal A., Bray F., Center M. M. et al. Global cancer statistics. CA Cancer J Clin: 2011; 61 69 90
33. Fattovich G., Stroffolini T., Zagni I. et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology: 2004; 127 S35 S50
34. Demierre M. F., Higgins P. D., Gruber S. B. et al. Statins and cancer prevention. Nat Rev Cancer: 2005; 5 930 942
35. Rao S., Porter D. C., Chen X. et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA: 1999; 96 7797 7802
36. Hamelin B. A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci: 1998; 19 26 37
37. Siddharth S., Preet Paul S., Abha Goyal S. et al. Associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology: 2013; 144 323 332
38. David E. Cohen Frank A. et al. An assessment of statin safety by hepatologists. Am J Cardiol: 2006; 97 [suppl] 77C 81C